Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly

U.S. stocks rose Monday, with the Nasdaq up 1% and the semiconductor ETF SOXX on pace to end a nine-session losing streak, though the rebound was tepid and CoreWeave fell below $60 to a new low for the year. WTI crude gained about $2 to around $103 per barrel, stoking inflation concerns and pushing the 10-year Treasury yield higher. Bank of America raised Eli Lilly’s price target to $1,397 from $1,341 after its survey found oral GLP-1 drugs and Medicare’s Bridge program were expanding the market; respondents estimated Foundayo had 27% of U.S. oral GLP-1 new starts and projected 40% share by 2028/29.

Analysis

The semiconductor rebound looks more like a fragile positioning reset than a confirmed risk-on turn: SOXX fading intraday while CRWV makes a fresh low argues that investors are not yet comfortable underwriting AI-infrastructure duration risk. Higher oil and Treasury yields compound that pressure by lifting discount rates and threatening to reprice long-duration growth; a sustained oil move would also raise input and household-cost risks beyond tech. The near-term test is whether yields stabilize and chip leadership broadens, rather than whether the index merely ends a losing streak.

The more durable signal is GLP-1 market expansion, but the survey supports demand breadth—not yet earnings durability. New-to-category patients reduce the immediate cannibalization concern, while pill share gains could still redistribute value between LLY and NVO. Medicare access may accelerate adoption, but verify persistence, net pricing, and the program’s duration before capitalizing survey-based starts into long-run estimates. LLY’s Oct. 29 report is the key 1–3 month validation point; over 6–18 months, reimbursement and supply capacity matter more than oral share alone. The contrarian risk is that the market treats temporary access and physician expectations as recurring demand. No compelling signal here supports chasing the broad semiconductor bounce.

Key Decisions for Investors

• Keep SOXX exposure tactical rather than adding to the bounce. Reassess only if the ETF holds a recovery and leadership broadens; renewed yield increases or continued weakness in CRWV would falsify the risk-on read.
• Treat LLY versus NVO as a relative-value watch, not an automatic pair trade. Around LLY’s Oct. 29 results, look for evidence that oral starts translate into persistent users, favorable net pricing, and guidance support; avoid adding on survey share estimates alone.
• Monitor WTI and the 10-year yield together over the next several sessions. A sustained oil rise with renewed yield pressure would favor reducing duration-sensitive growth exposure; a reversal in either would weaken that macro headwind.
• Before underwriting the GLP-1 demand thesis, verify Medicare Bridge timing and continuation terms, prescription persistence, and supply availability. A coverage cliff, weak refill behavior, or flat guidance would challenge the expansion narrative.